Posted in | News | Nanomedicine

Sorrento and IGDRASOL to Present Nanomedicine Platform Updates at 4th International Nanomedicine Conference

Sorrento Therapeutics, Inc. (Sorrento) and IGDRASOL announced today that the companies will present Phase III interim data analysis of Cynviloq in metastatic breast cancer (MBC) patients showing significantly improved overall response rate (ORR) compared to generic paclitaxel as well as updates of their nanomedicine platform, which is being developed for multiple cancer indications in late-stage clinical trials, at the 4th International Nanomedicine Conference in Sydney Australia (July 1st - 3rd, 2013).

Sorrento has the right to acquire IGDRASOL pursuant to a previously-announced option agreement, entered into in March 2013.

Cynviloq™ (IG-001) is a next-generation, branded, micellar diblock copolymeric paclitaxel formulation currently approved and marketed in several countries as Genexol-PM®. Cynviloq™ has completed Phase 1 or 2 trials in MBC, non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and bladder cancer in the U.S. and/or ex-U.S. IGDRASOL is preparing for an "End of Phase 2" meeting scheduled with the U.S. Food & Drug Administration (FDA) in July 2013, regarding the clinical development of Cynviloq™. As an injectable nanoparticle formulation of paclitaxel, Cynviloq™ may be eligible for approval through the FDA's 505(b)(2) bioequivalence regulatory pathway versus albumin-bound paclitaxel (nab-paclitaxel; Abraxane®) in its currently approved MBC and NSCLC indications.

Interim data analysis from an ongoing Phase III clinical study of Cynviloq™ in MBC patients conducted in South Korea indicates improved ORR vs. Taxol (40% vs. 26%, respectively, p = 0.03). "This clear ORR improvement of Cynviloq™ over generic paclitaxel closely mimics that of Abraxane's registration trial results, and is a further validation of the similarity in efficacy between these two different formulations," said Vuong Trieu Ph.D., CEO of IGDRASOL. The oral presentations are entitled:

  • "A Non-biologic Nanoparticle Paclitaxel for the Treatment of Pancreatic Cancer," authored by Vuong Trieu, Catherine Cheng, Larn Hwang, Chao Hsiao, and Kouros Motamed.
  • "IG-001 for Metastatic Breast Cancer¯Interim Analysis of a Phase 3 Trial," authored by Vuong Trieu, Larn Hwang, Chao Hsiao, Kouros Motamed, and Chulho Park.
  • "CynviloqTM/IG-001¯A Non-Biologic Nanoparticle Paclitaxel for the Treatment of Solid Tumors," authored by Kouros Motamed, Catherine Cheng, Larn Hwang, Chao Hsiao, and Vuong Trieu.

About Cynviloq™

Cynviloq™ (or IG-001; a paclitaxel-loaded micellar diblock copolymer) is a next-generation branded paclitaxel formulation currently approved and on the market in several countries as Genexol-PM®.

Press release avilable from http://www.prnewswire.com/

Source: http://www.sorrentotherapeutics.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit
Azthena logo

AZoM.com powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from AZoNetwork.com.

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.